Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.370 -0.100 (-4.05%)
Streaming Delayed Price Updated: 3:52 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,092,252
Open 2.500
Bid (Size) 2.360 (77)
Ask (Size) 2.370 (99)
Prev. Close 2.470
Today's Range 2.295 - 2.509
52wk Range 0.7000 - 3.400
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets

Performance

YTD
-18.84%
-18.84%
1 Month
-18.56%
-18.56%
3 Month
-15.05%
-15.05%
6 Month
-15.05%
-15.05%
1 Year
+47.20%
+47.20%

More News

Read More
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Via Benzinga
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Via Benzinga
Exposures Product Safety
Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
Via InvestorPlace
Why Is GreenPower Motor (GP) Stock Down 36% Today?
Via InvestorPlace
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Esperion Reports First Quarter 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming May Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2024 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.